New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:13 EDTVRTXVertex announced data on on ALS-2200 are being presented at AASLD
Vertex Pharmaceuticals announced that data on ALS-2200, VX-135, an oral medicine Vertex is developing for the treatment of hepatitis C, are being presented for the first time at The Liver Meeting, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD. Data from viral kinetic study showed rapid reduction of HCV RNA with ALS-2200 (VX-135), Vertex’s oral nucleotide analogue in development for the treatment of hepatitis C.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for VRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use